Clinical Trial Update: Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) to Evaluate Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-associated Lymphoma

View source ↗

Summary

A completed clinical trial evaluating fluorodeoxyglucose-positron emission tomography (FDG-PET) for evaluating autoimmune lymphoproliferative syndrome (ALPS) an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Lymphoproliferative Syndrome
• Lymphoma

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Lymphoproliferative Disorders, Lymphoma | Status: COMPLETED